Targeted Therapies for Pancreatic Cancer
Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/10/2/36 |
| id |
doaj-0cdce28bd17643d29d1821610d1d73ba |
|---|---|
| record_format |
Article |
| spelling |
doaj-0cdce28bd17643d29d1821610d1d73ba2020-11-24T21:49:58ZengMDPI AGCancers2072-66942018-01-011023610.3390/cancers10020036cancers10020036Targeted Therapies for Pancreatic CancerIdoroenyi Amanam0Vincent Chung1Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USADepartment of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USAPancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies.http://www.mdpi.com/2072-6694/10/2/36targeted therapypersonalized medicinepancreas |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Idoroenyi Amanam Vincent Chung |
| spellingShingle |
Idoroenyi Amanam Vincent Chung Targeted Therapies for Pancreatic Cancer Cancers targeted therapy personalized medicine pancreas |
| author_facet |
Idoroenyi Amanam Vincent Chung |
| author_sort |
Idoroenyi Amanam |
| title |
Targeted Therapies for Pancreatic Cancer |
| title_short |
Targeted Therapies for Pancreatic Cancer |
| title_full |
Targeted Therapies for Pancreatic Cancer |
| title_fullStr |
Targeted Therapies for Pancreatic Cancer |
| title_full_unstemmed |
Targeted Therapies for Pancreatic Cancer |
| title_sort |
targeted therapies for pancreatic cancer |
| publisher |
MDPI AG |
| series |
Cancers |
| issn |
2072-6694 |
| publishDate |
2018-01-01 |
| description |
Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies. |
| topic |
targeted therapy personalized medicine pancreas |
| url |
http://www.mdpi.com/2072-6694/10/2/36 |
| work_keys_str_mv |
AT idoroenyiamanam targetedtherapiesforpancreaticcancer AT vincentchung targetedtherapiesforpancreaticcancer |
| _version_ |
1725886152409350144 |